The size of the Atopic Dermatitis Treatment Market in the Asia Pacific is forecasted to grow USD 5.02 billion by 2026 from USD 2.63 billion in 2021, hiking at a CAGR of 13.8% from 2021 to 2026.
Y-O-Y growth in the incidence of atopic dermatitis in children in the Asia Pacific countries is predicted to enhance the region's market growth. The on-going efforts made by the key players for the development of novel drugs are driving market growth. Regular increases in disorders among the emerging economies are driving the growth. Growing healthcare expenses per head and upgraded health insurance coverage are stimulating the growth of the APAC region. An increase in discretionary expenses, climatic changes, and escalating pollution levels and research institutes and pharmaceutical companies' research and development efforts lead to the development of new drugs in the region.
The cost of biologics is predicted to impede the market in both developed and underdeveloped countries. Lack of awareness in patients, uptake of generic topical drugs, and pediatric population existing as the most massive segment act as an obstacle in the region's market growth. Curbing from the approval process for new drugs is inhibiting market growth.
This research report on the Asia Pacific Atopic Dermatitis Treatment Market has been segmented and sub-segmented into the following categories:
The Asia Pacific Atopic Dermatitis Treatment Market is predicted to be the fastest-growing market in the forecast mentioned above period. Rapidly growing population, changing lifestyles, and a paradigm shift towards western lifestyles, increasing R&D, and large target patient pool are the reasons attributable to the observable trend mentioned above.
Countries like India, China, and South Korea are to invest highly in the healthcare domain. India and South Korea are to produce considerable demand for atopic dermatitis treatment in the region. In India, around 20-30% of the population is suffering from at least one allergic disease. Key players of this region are to make considerable investments in the research and development of new drugs is to accelerate the market. China is expected to lead the atopic dermatitis market in the APAC region due to rising awareness of skin problems in infants and small children. Uplifting healthcare infrastructure and services scenario among the developing economies and existence of enormous targeted patient count and considerable growth in generic drugs for the market, making a substantial contribution to the development of emerging countries like India, South Korea, and China. Other factors like seasonal allergies, severe climatic conditions, and varying humidity levels boost the region's growth.
Companies that are leading the Asia Pacific Atopic Dermatitis Treatment Market Profiled in the Report are Astellas Pharma Inc., Valeant Pharmaceuticals International, Inc., and Sanofi S.A. Other players in the market include Anacor Pharmaceuticals, Inc. Meda Pharmaceuticals, Regeneron Pharmaceuticals Inc., and Novartis International AG, Pfizer Inc.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Treatment Type
5.1.2 Drug Treatment
126.96.36.199 Calcineurin Inhibitors
5.1.3 Radiation Treatment
5.1.4 Y-o-Y Growth Analysis, By Treatment Type
5.1.5 Market Attractiveness Analysis, By Treatment Type
5.1.6 Market Share Analysis, By Treatment Type
5.2 Route of administration
5.2.4 Y-o-Y Growth Analysis, By Route of administration
5.2.5 Market Attractiveness Analysis, By Route of administration
5.2.6 Market Share Analysis, By Route of administration
5.3 Distribution Channel
5.3.2 Hospital Pharmacies
5.3.3 Retail Pharmacies
5.3.4 Online Pharmacies
5.3.5 Y-o-Y Growth Analysis, By Distribution Channel
5.3.6 Market Attractiveness Analysis, By Distribution Channel
5.3.7 Market Share Analysis, By Distribution Channel
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
188.8.131.52 By Geographical Area
184.108.40.206 By Treatment Type
220.127.116.11 By Route of administration
18.104.22.168 By Distribution Channel
6.1.4 Market Attractiveness Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Treatment Type
188.8.131.52 By Route of administration
184.108.40.206 By Distribution Channel
6.1.5 Market Share Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Treatment Type
22.214.171.124 By Route of administration
126.96.36.199 By Distribution Channel
6.5 South Korea
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Astellas Pharma Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Sanofi S.A.
8.3 Valeant Pharmaceuticals International, Inc.
8.4 Novartis International AG
8.5 Pfizer Inc.
8.6 Meda Pharmaceuticals
8.7 Regeneron Pharmaceuticals Inc.
8.8 Anacor Pharmaceuticals, Inc.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures